BioSpace News Archive

Matinas BioPharma, a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

TELA Bio, Inc. reported financial results for the second quarter ended June 30, 2023.

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, reported financial results and provided a corporate update for the second quarter ended June 30, 2023.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, provided a corporate update and reported second quarter 2023 financial results.

Avadel Pharmaceuticals plc today provided a corporate update and announced its financial results for the second quarter ended June 30, 2023.

Today, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-122, a dual-functioning monoclonal antibody. Furthermore, the company successfully completed a $75M Series A financing.

Nanoscope Therapeutics Inc. presented key results from its Phase 2 clinical trial, STARLIGHT, at the American Society of Retina Specialists (ASRS) annual meeting in Seattle last week.

Precigen, Inc. today announced that the US Food and Drug Administration (FDA) has agreed that the ongoing Phase 1/2 single arm study (NCT04724980) of the first-in-class investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP) will serve as pivotal for the purpose of filing an accelerated approval request for licensure.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the second quarter of 2023.

Landos Biopharma, Inc. today provided a business update and announced financial results for the second quarter ended June 30, 2023.